Allogene Therapeutics, Inc. (Nasdaq: ALLO) Rings The Nasdaq Stock Market Opening Bell In Celebration of Its IPO
Allogene Therapeutics, Inc. (Nasdaq: ALLO), clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T-cell (AlloCAR T™) therapies for cancer, visited the Nasdaq MarketSite in Times Square in celebration of its initial public offering (IPO).
Format
JPEG
Source
Nasdaq, Inc.